Annual report pursuant to Section 13 and 15(d)

Severance Charges

Severance Charges
12 Months Ended
Dec. 31, 2018
Restructuring And Related Activities [Abstract]  
Severance Charges



As a requirement for the closing of the Arrangement, OncoGenex terminated the employment of one senior executive. Severance payable at the date of the transaction was $1.2 million and has been accounted for as part of the purchase price allocation (Note 4—Intangibles). The severance payable was settled following the completion of the Arrangement and no amounts were owing as at December 31, 2018.